High Content Imaging and Analysis Enable Quantitative in Situ Assessment of CYP3A4 Using Cryopreserved Differentiated HepaRG Cells

Journal of Toxicology

Volumn 2014, Issue , 2014, Pages

  Ranade, Aarati R ^a   Wilson, Melinda S ^b   McClanahan, Amy M ^c   Ball, Andrew J ^a  

^a MILLIPORE CORPORATION   (United States)

^b DONALD DANFORTH PLANT SCIENCE CENTER   (United States)

^c BARNES JEWISH HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CYTOCHROME P450 1A2; CYTOCHROME P450 3A4; RIFAMPICIN;

ARTICLE; CELL DENSITY; CELL DIFFERENTIATION; CELL FUNCTION; CONTROLLED STUDY; CRYOPRESERVATION; ENZYME ACTIVITY; EPITHELIUM CELL; HEPARG CELL; HEPG2 CELL LINE; HIGH CONTENT ANALYSIS; HIGH THROUGHPUT SCREENING; HUMAN; HUMAN CELL; IMAGE ANALYSIS; IMAGING AND DISPLAY; IN VITRO STUDY; LIVER CELL; LIVER CELL CULTURE; LIVER TOXICITY; NUCLEAR SIZE; PRIORITY JOURNAL; PROCEDURES CONCERNING CELLS; QUANTITATIVE ANALYSIS;

EID: 84930923987     PISSN: 16878191     EISSN: 16878205     Source Type: Journal    
DOI: 10.1155/2014/291054     Document Type: Article

References (30)

1. F. Peter Guengerich, "Mechanisms of drug toxicity and relevance to pharmaceutical development, " Drug Metabolism and Pharmacokinetics, vol. 26, no. 1, pp. 3-14, 2011.
2. J. R. Senior, "Drug hepatotoxicity from a regulatory perspective, " Clinics in Liver Disease, vol. 11, no. 3, pp. 507-524, 2007.
3. P. McGonigle and B. Ruggeri, "Animal models of human disease: challenges in enabling translation, " Biochemical Pharmacology, vol. 87, pp. 162-171, 2014.
4. M. J. Gómez-Lechón, M. T. Donato, J. V. Castell, and R. Jover, "Human hepatocytes as a tool for studying toxicity and drug metabolism, " Current Drug Metabolism, vol. 4, no. 4, pp. 292-312, 2003.
5. J. V. Castell, R. Jover, C. P. Martínez-Jiménez, and M. J. Gómez-Lechón, "Hepatocyte cell lines: their use, scope and limitations in drug metabolism studies, " Expert Opinion on Drug Metabolism & Toxicology, vol. 2, pp. 183-212, 2006.
6. I. S. Behbahan, Y. Duan, A. Lam et al., "New approaches in the diferentiation of human embryonic stem cells and induced pluripotent stem cells toward hepatocytes, " Stem Cell Reviews and Reports, vol. 7, no. 3, pp. 748-759, 2011.
7. A. Guillouzo, A. Corlu, C. Aninat, D. Glaise, F. Morel, and C. Guguen-Guillouzo, "The human hepatoma HepaRG cells: A highly diferentiated model for studies of liver metabolism and toxicity of xenobiotics, " Chemico-Biological Interactions, vol. 168, no. 1, pp. 66-73, 2007.
8. P. Gripon, S. Rumin, S. Urban et al., "Infection of a human hepatoma cell line by hepatitis B virus, " Proceedings of the National Academy of Sciences of the United States of America, vol. 99, no. 24, pp. 15655-15660, 2002.
9. R. Parent, M.-J. Marion, L. Furio, C. Tŕepo, and M.-A. Petit, "Origin and characterization of a human bipotent liver progenitor cell line, " Gastroenterology, vol. 126, no. 4, pp. 1147-1156, 2004.
10. A. Rogue, C. Lambert, C. Spire, N. Claude, and A. Guil-louzo, "Interindividual variability in gene expression profles in human hepatocytes and comparison with HepaRG cells, " Drug Metabolism and Disposition, vol. 40, no. 1, pp. 151-158, 2012.
11. T. B. Andersson, K. P. Kanebratt, and J. G. Kenna, "The HepaRG cell line: a unique in vitro tool for understanding drug metabolism and toxicology in human, " Expert Opinion on Drug Metabolism & Toxicology, vol. 8, no. 7, pp. 909-920, 2012.
12. C. Guguen-Guillouzo and A. Guillouzo, "General review on in vitro hepatocyte models and their applications, " Methods in Molecular Biology, vol. 640, pp. 1-40, 2010.
13. C. Guguen-Guillouzo, A. Corlu, and A. Guillouzo, "Stem cell-derived hepatocytes and their use in toxicology, " Toxicology, vol. 270, no. 1, pp. 3-9, 2010.
14. U. Zanelli, N. P. Caradonna, D. Hallifax, E. Turlizzi, and J. B. Houston, "Comparison of cryopreserved HepaRG cells with cryopreserved human hepatocytes for prediction of clearance for 26 drugs, " Drug Metabolism and Disposition, vol. 40, no. 1, pp. 104-110, 2012.
15. M. Persson, A. F. Løye, M. Jacquet et al., "High-content analysis/screening for predictive toxicology: application to hep-atotoxicity and genotoxicity, " Basic & Clinical Pharmacology & Toxicology, vol. 115, no. 1, pp. 18-23, 2014.
16. J. J. Xu, P. V. Henstock, M. C. Dunn, A. R. Smith, J. R. Chabot, and D. de Graaf, "Cellular imaging predictions of clinical drug-induced liver injury, " Toxicological Sciences, vol. 105, no. 1, pp. 97-105, 2008.
17. P. J. O'Brien, W. Irwin, D. Diaz et al., "High concordance of drug-induced human hepatotoxicity with in vitro cytotoxicity measured in a novel cell-based model using high content screening, " Archives of Toxicology, vol. 80, no. 9, pp. 580-604, 2006.
18. K. A. Giuliano, A. H. Gough, D. Lansing Taylor, L. A. Vernetti, and P. A. Johnston, "Early safety assessment using cellular systems biology yields insights into mechanisms of action, " Journal of Biomolecular Screening, vol. 15, no. 7, pp. 783-797, 2010.
19. H. Garside, K. F. Marcoe, J. Chesnut-Speelman et al., "Evaluation of the use of imaging parameters for the detection of compound-induced hepatotoxicity in 384-well cultures of HepG2 cells and cryopreserved primary human hepatocytes, " Toxicology in Vitro, vol. 28, pp. 171-181, 2014.
20. U. M. Zanger and M. Schwab, "Cytochrome P450 enzymes in drug metabolism: regulation of gene expression, enzyme activities, and impact of genetic variation, " Pharmacology & Terapeutics, vol. 138, no. 1, pp. 103-141, 2013.
21. M. S. Wilson, J. R. Graham, and A. J. Ball, "Multiparametric high content analysis for assessment of neurotoxicity in diferenti-ated neuronal cell lines and human embryonic stem cell-derived neurons, " Neurotoxicology, vol. 42, pp. 33-48, 2014.
22. S. Arastu-Kapur, J. L. Anderl, M. Kraus et al., "Nonprotea-somal targets of the proteasome inhibitors bortezomib and carflzomib: a link to clinical adverse events, " Clinical Cancer Research, vol. 17, no. 9, pp. 2734-2743, 2011.
23. U. M. Zanger and M. Schwab, "Cytochrome P450 enzymes in drug metabolism: regulation of gene expression, enzyme activities, and impact of genetic variation, " Pharmacology and Terapeutics, vol. 138, no. 1, pp. 103-141, 2013.
24. H. H. J. Gerets, K. Tilmant, B. Gerin et al., "Characterization of primary human hepatocytes, HepG2 cells, and HepaRG cells at the mRNA level and CYP activity in response to inducers and their predictivity for the detection of human hepatotoxins, " Cell Biology and Toxicology, vol. 28, no. 2, pp. 69-87, 2012.
25. T. R. van Vleet, P. J. Klein, and R. A. Coulombe Jr., "Metabolism and cytotoxicity of afatoxin B1 in cytochrome P-450-expressing human lung cells, " Journal of Toxicology and Environmental Health A, vol. 65, no. 12, pp. 853-867, 2002.
26. D. Mueller, L. Krämer, E. Hofmann, S. Klein, and F. Noor, "3D organotypic HepaRG cultures as in vitro model for acute and repeated dose toxicity studies, " Toxicology in Vitro, vol. 28, no. 1, pp. 104-112, 2014.
27. R. Joss̈e, C. Aninat, D. Glaise et al., "Long-term functional stability of human HepaRG hepatocytes and use for chronic toxicity and genotoxicity studies, " Drug Metabolism and Disposition, vol. 36, no. 6, pp. 1111-1118, 2008.
28. S. Anthérieu, C. Chesńe, R. Li et al., "Stable expression, activity, and inducibility of cytochromes P450 in diferentiated HepaRG cells, " Drug Metabolism and Disposition, vol. 38, no. 3, pp. 516-525, 2010.
29. J. L. Anderl, S. Redpath, and A. J. Ball, "A neuronal and astrocyte co-culture assay for high content analysis of neurotoxicity, " Journal of Visualized Experiments, no. 27, 2009.
30. P. J. Lee, P. J. Hung, and L. P. Lee, "An artifcial liver sinusoid with a microfuidic endothelial-like barrier for primary hepatocyte culture, " Biotechnology and Bioengineering, vol. 97, no. 5, pp. 1340-1346, 2007.